Third Rock Ventures Launches Fulcrum Therapeutics with $55M Series A Investment
Third Rock Ventures, LLC announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes.
Fulcrum was established with $55 million in Series A financing to further develop a cross-disciplinary product engine to identify and modulate gene regulatory targets core to disease. Through its product engine, Fulcrum will develop a robust across therapeutic areas, spearheaded by two initial programs in genetic diseases.
Read the Fulcrum Therapeutics press release for more information.